Neoadjuvant Selpercatinib for Stage <scp>IIIA</scp> Primary Pulmonary Adenocarcinoma With <scp>RET</scp> Fusion: A Case Report
Selpercatinib represents the first targeted therapeutic agent approved for RET fusion-positive unresectable non-small cell lung cancers. This case report describes a patient with stage IIIA (cT2aN2M0) RET fusion-mutated adenocarcinoma of the left upper lobe. Following 9 months of selpercatinib therapy, the patient achieved clinical downstaging and subsequently underwent curative resection. Postoperative pathologic staging was IIA (ypT1bN1M0). Adjuvant therapy with selpercatinib was continued postoperatively. The patient remained recurrence-free on continued follow-up with 17 months since diagnosis and 8 months since surgery.
Authors
- Yizhuo Hu (ORCID: https://orcid.org/0000-0002-4520-4520)
- Chuanyong Mu (ORCID: https://orcid.org/0000-0002-1370-6542)
- Jun Zhao (ORCID: https://orcid.org/0000-0002-8656-0636)
- Chang Li (ORCID: https://orcid.org/0000-0002-4368-4276)
- Zihan Cui (ORCID: https://orcid.org/0000-0002-3148-7865)
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Respirology Case Reports
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/rcr2.70390
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Soochow University